Table 2. Multivariate-adjusted eGFRcre according to tertile of serum (EPA+DHA):AA ratio in the Sasayama study, 2012–2013.
Tertile of serum (EPA+DHA):AA | P valuea | |||
T1 | T2 | T3 | ||
Men | ||||
Number of participants | 78 | 80 | 79 | |
Range of (EPA+DHA):AA ratio | 0.409–0.904 | 0.908–1.318 | 1.323–3.188 | |
Sex- and age-adjusted mean eGFRcre (95% CI) | 72.1 (68.8–75.4) | 72.2 (69.1–75.4) | 75.2 (72.0–78.5) | 0.322 |
Multivariate-adjusted mean eGFRcre (95% CI) (Model 1)b | 71.3 (68.0–74.6) | 72.5 (69.4–75.6) | 75.8 (72.6–79.0) | 0.139 |
Multivariate-adjusted mean eGFRcre (95% CI) (Model 2)c | 71.3 (68.0–74.6) | 72.5 (69.4–75.6) | 75.8 (72.6–79.0) | 0.147 |
Women | ||||
Number of participants | 103 | 104 | 105 | |
Range of (EPA+DHA):AA ratio | 0.338–0.925 | 0.929–1.282 | 1.283–2.777 | |
Sex- and age-adjusted mean eGFRcre (95% CI) | 73.2 (70.7–75.7) | 73.2 (70.9–75.5) | 73.0 (70.7–75.3) | 0.989 |
Multivariate-adjusted mean eGFRcre (95% CI) (Model 1)b | 73.2 (70.6–75.7) | 73.2 (70.9–75.5) | 73.1 (70.7–75.4) | 0.998 |
Multivariate-adjusted mean eGFRcre (95% CI) (Model 2)c | 73.2 (70.6–75.7) | 73.1 (70.8–75.5) | 73.1 (70.8–75.5) | 1.000 |
Men and women combined | ||||
Number of participants | 184 | 181 | 184 | |
Range of (EPA+DHA):AA ratio | 0.338–0.925 | 0.928–1.301 | 1.301–3.188 | |
Sex- and age-adjusted mean eGFRcre (95% CI) | 72.7 (70.7–74.7) | 73.1 (71.2–75.0) | 73.7 (71.8–75.6) | 0.776 |
Multivariate-adjusted mean eGFRcre (95% CI) (Model 1)b | 72.3 (70.3–74.2) | 73.3 (71.4–75.2) | 74.0 (72.1–75.9) | 0.507 |
Multivariate-adjusted mean eGFRcre (95% CI) (Model 2)c | 72.2 (70.2–74.2) | 73.3 (71.4–75.1) | 74.0 (72.1–75.9) | 0.476 |
AA, arachidonic acid; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; GFR, glomerular filtration rate.
aP value for ANCOVA.
bMultivariate-adjusted (Model 1): eGFR adjusted for age, sex, BMI, hypertension, diabetes, HDL-C, LDL-C, medication for dyslipidemia, current smoking, and current drinking.
cMultivariate-adjusted (Model 2): eGFR adjusted for variables in model 1 plus log-transformed high-sensitivity C-reactive protein.